Stockscreener 앱 받기
0.6767
2.44%
0.0164
전일 마감가:
$0.6603
열려 있는:
$0.6601
하루 거래량:
15,676
Relative Volume:
0.09
시가총액:
$94.24M
수익:
$78.46M
순이익/손실:
$2.75M
주가수익비율:
67.67
EPS:
0.01
순현금흐름:
$-12.42M
1주 성능:
-8.20%
1개월 성능:
+43.31%
6개월 성능:
+69.10%
1년 성능:
-6.06%
1일 변동 폭
$0.635
$0.6996
1주일 범위
$0.635
$0.73
52주 변동 폭
$0.331
$0.8325
엑스탄트 Stock (XTNT) Company Profile
명칭
Xtant Medical Holdings Inc
전화
406-388-0480
주소
664 Cruiser Lane, Belgrade, MT
XTNT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XTNT
Xtant Medical Holdings Inc
|
0.6764 | 95.02M | 78.46M | 2.75M | -12.42M | 0.01 |
|
ABT
Abbott Laboratories
|
133.24 | 231.29B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.94 | 157.07B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.12 | 146.67B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.29 | 104.07B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.51 | 44.71B | 5.54B | 4.18B | 623.10M | 7.00 |
엑스탄트 Stock (XTNT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-05 | 개시 | BTIG Research | Buy |
| 2018-11-15 | 재확인 | Maxim Group | Buy |
| 2018-02-14 | 재확인 | Maxim Group | Buy |
엑스탄트 주식(XTNT)의 최신 뉴스
Xtant Medical Unveils OsteoFactor Pro for Bone Healing - Precedence Research
Xtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Xtant Medical launches OsteoFactor Pro for bone repair By Investing.com - Investing.com South Africa
Xtant Medical Announces the Launch of OsteoFactor Pro™ - Ortho Spine News
Xtant Medical Holdings, Inc. Announces the Launch of OsteoFactor Pro - marketscreener.com
Xtant Medical launches OsteoFactor Pro for bone repair - Investing.com
Xtant Medical Introduces First-Ever Complete Orthobiologic Portfolio with New Bone Growth Technology - Stock Titan
Xtant Medical’s Earnings Call Highlights Growth and Optimism - TipRanks
Earnings call transcript: Xtant Medical Q1 2025 shows revenue growth and stock surge - Investing.com Nigeria
Xtant Medical outlines 8–11% revenue growth target for 2025 as company completes vertical integration and launches new products - MSN
Xtant Medical (XTNT) Files to Sell Over 73 Million Shares of Com - GuruFocus
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call Transcript - Insider Monkey
Xtant Medical’s Q1 2025 revenue increases 18% to USD 32.9M - Medical Buyer
Xtant Medical Reports Strong Q1 2025 Results - TipRanks
Xtant Medical Q1 2025 Earnings Call Transcript - MarketBeat
Xtant Medical Reports First Quarter 2025 Financial Results - Yahoo Finance
Xtant Medical Holdings Inc (XTNT) Q1 2025: Everything You Need T - GuruFocus
Xtant Medical (XTNT) Projected to Post Quarterly Earnings on Monday - Defense World
Xtant Medical Sets Q1 2025 Earnings Date: MedTech Leader to Discuss Surgical Solutions Growth on May 12 - Stock Titan
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Shares Acquired by Renaissance Technologies LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
How to interpret Xtant Medical Holdings Inc (XTNT)’s stock chart patterns - uspostnews.com
Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance - GuruFocus
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Xtant Medical Holdings (XTNT) and Medtronic (MDT) - The Globe and Mail
Xtant Medical Holdings Inc (AMEX: XTNT) Has Great Upside Potential - stocksregister.com
Xtant Medical announces secondary private sale of existing shares - Medical Buyer
Xtant Medical Ends Investor Agreement After Share Sale - TipRanks
Xtant Medical secures investor support, projects Q1 revenue growth By Investing.com - Investing.com South Africa
Xtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19% - Ortho Spine News
Xtant Medical Announces Secondary Private Sale Of Existing Shares By Orbimed - marketscreener.com
Major Shakeup: OrbiMed Sells Entire Xtant Medical Stake as Revenue Surges 19% - Stock Titan
Orbimed advisors sells Xtant Medical stock for $30.7 million - Investing.com
Xtant Medical shares change hands in major stock purchase - Investing.com
Xtant Medical shares change hands in major stock purchase By Investing.com - Investing.com India
Xtant Medical Expands Product Portfolio with Launch of its own Viable Bone Matrix, OsteoVive(R) Plus - ACCESS Newswire
Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Spinal Fusion Device Market Forecast Report and Company Analysis 2025-2033 Featuring Medtronic, Stryker, Zimmer Biomet, Orthofix Medical, NuVasive, Globus Medical, Xtant Medical, and Alphatec – Ortho Spine News - OrthoSpineNews
Spinal Fusion Device Market Forecast Report and Company - GlobeNewswire
Xtant Medical (NYSEAMERICAN:XTNT) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Xtant Medical Faces Risk of Share Distribution by Major Stakeholder, Threatening Stock Stability - MSN
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2024 Earnings Call Transcript - Insider Monkey
Xtant Medical’s Earnings Call: Mixed Outlook with Growth Plans - TipRanks
Earnings call transcript: Xtant Medical Q4 2024 misses EPS, stock drops - Investing.com India
Earnings call transcript: Xtant Medical Q4 2024 misses EPS, stock drops By Investing.com - Investing.com South Africa
Xtant Medical stock target cut to $2 at BTIG, retains buy rating By Investing.com - Investing.com South Africa
Xtant Medical stock target cut to $2 at BTIG, retains buy rating - Investing.com
엑스탄트 (XTNT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.61%
0.78%
자본화:
|
볼륨(24시간):